文献速递生殖医学

FSHR与FSHB基因多态性对卵巢反应的影响:欧洲与亚洲前瞻性多中心研究

The effect of polymorphisms in FSHR and FSHB genes on ovarian response: a prospective multicenter multinational study in Europe and Asia.
PubMed 文献 · Hum Reprod · 2021-01-01

该前瞻性多中心研究纳入368例预测正常反应者,采用固定150 IU rFSH拮抗剂方案,发现FSHR SNPs(rs6165、rs6166、rs1394205)对获卵数等卵巢反应指标有统计学显著影响,但临床相关性极小;FSHB rs10835638罕见。不推荐在启动刺激前常规检测这些SNPs。

要点

  • FSHR rs6166 G等位基因携带者获卵数显著少于AA型(13.54 vs 14.81,EMD -1.47)。
  • FSHR rs1394205 A等位基因携带者获卵数显著少于GG型(13.33 vs 15.06,EMD -1.69)。
  • rs6166 A/G型低反应者比例显著高于AA型(55.9% vs 28.4%,ORadj 1.87)。

核心结论

  • FSHR SNPs对预测正常反应者的卵巢反应有统计学显著影响,但临床相关性极小。
  • 不推荐在rFSH刺激前常规检测FSHR rs6165、rs6166、rs1394205及FSHB rs10835638。

研究设计与样本

  • 前瞻性多中心跨国研究,纳入368例来自越南、比利时和西班牙的预测正常反应者(欧洲168例,亚洲200例),研究时间为2016年11月至2019年6月。
  • 所有患者采用拮抗剂方案,固定每日150 IU rFSH直至触发,取卵前采血提取DNA并对四个SNP进行基因分型。
  • 纳入标准为年龄<38岁、首次或第二次卵巢刺激周期的预测正常反应者,实验室人员和临床医生分别对临床结果和基因分型设盲。

主要发现

  • FSHR衍生等位基因纯合SNP prevalence:rs6166 G/G 15.8%,rs6165 G/G 34.8%,rs1394205 A/A 14.1%,白人与亚洲女性间差异显著(P < 0.001)。
  • FSHB rs10835638 (c.-211 G>T) 非常罕见(0.5%)。
  • FSHR rs6166 G等位基因携带者获卵数少于AA型(13.54 ± 0.46 vs 14.81 ± 0.61,EMD -1.47,95% CI -2.82至-0.11)。
  • FSHR rs1394205 A等位基因携带者获卵数少于G/G型(13.33 ± 0.41 vs 15.06 ± 0.68,EMD -1.69,95% CI -3.06至-0.31)。
  • FSHR rs6166 A/G型低反应者比例高于A/A型(55.9%,n=57 vs 28.4%,n=29,ORadj 1.87,95% CI 1.08-3.24);FORT在各基因型间无显著差异。

关键数值与推荐

  • FSHR rs6166 G等位基因携带者FOI低于A/A型(EMD -13.47,95% CI -22.69至-4.24)。
  • FSHR rs6165 A/G型FOI低于A/A型(79.75 ± 3.35 vs 92.08 ± 6.23,EMD -13.81,95% CI -25.41至-2.21)。

临床怎么用

  • 基于该研究结果,在预测正常反应者中启动rFSH卵巢刺激前,不推荐常规进行FSHR rs6165、rs6166、rs1394205及FSHB rs10835638基因分型。
  • 临床决策应综合考虑其他因素,而非依赖这些SNP信息,因其在该人群中的临床影响极小。

局限性

  • 研究仅纳入相对年轻且卵巢储备正常的女性,外推至高龄人群需谨慎。
  • 因FSHB rs10835638 T/T基因型 prevalence 极低(n=2),未对该变异进行分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the presence of single nucleotide polymorphisms (SNPs) in the FSH receptor gene (FSHR) and/or FSH beta subunit-encoding gene (FSHB) influence ovarian response in predicted normal responders treated with rFSH? SUMMARY ANSWER: The presence of FSHR SNPs (rs6165, rs6166, rs1394205) has a statistically significant impact in ovarian response, although this effect is of minimal clinical relevance in predicted normal responders treated with a fixed dose of 150 IU rFSH. WHAT IS KNOWN ALREADY: Ovarian reserve markers have been a breakthrough in response prediction following ovarian stimulation. However, a significant percentage of patients show a disproportionate lower ovarian response, as compared with their actual ovarian reserve. Studies on pharmacogenetics have demonstrated a relationship between FSHR or FSHB genotyping and drug response, suggesting a potential effect of individual genetic variability on ovarian stimulation. However, evidence from these studies is inconsistent, due to the inclusion of patients with variable ovarian reserve, use of different starting gonadotropin doses, and allowance for dose adjustments during treatment. This highlights the necessity of a well-controlled prospective study in a homogenous population treated with the same fixed protocol. STUDY DESIGN, SIZE, DURATION: We conducted a multicenter multinational prospective study, including 368 patients from Vietnam, Belgium, and Spain (168 from Europe and 200 from Asia), from November 2016 until June 2019. All patients underwent ovarian stimulation followed by oocyte retrieval in an antagonist protocol with a fixed daily dose of 150 IU rFSH until triggering. Blood sampling and DNA extraction was performed prior to oocyte retrieval, followed by genotyping of four SNPs from FSHR (rs6165, rs6166, rs1394205) and FSHB (rs10835638). PARTICIPANTS/MATERIALS, SETTING, METHODS: Eligible were predicted normal responder women <38 years old undergoing their first or second ovarian stimulation cycle. Laboratory staff and clinicians were blinded to the clinical results and genotyping, respectively. The prevalence of hypo-responders, the number of oocytes retrieved, the follicular output rate (FORT), and the follicle to oocyte index (FOI) were compared between different FSHR and FSHB SNPs genotypes. MAIN RESULTS AND THE ROLE OF CHANCE: The prevalence of derived allele homozygous SNPs in the FSHR was rs6166 (genotype G/G) 15.8%, rs6165 (genotype G/G) 34.8%, and rs1394205 (genotype A/A) 14.1%, with significant differences between Caucasian and Asian women (P < 0.001). FSHB variant rs10835638 (c.-211 G>T) was very rare (0.5%). Genetic model analysis revealed that the presence of the G allele in FSHR variant rs6166 resulted in less oocytes retrieved when compared to the AA genotype (13.54 ± 0.46 vs 14.81 ± 0.61, estimated mean difference (EMD) -1.47 (95% CI -2.82 to -0.11)). In FSHR variant rs1394205, a significantly lower number of oocytes was retrieved in patients with an A allele when compared to G/G (13.33 ± 0.41 vs 15.06 ± 0.68, EMD -1.69 (95% CI -3.06 to -0.31)). A significantly higher prevalence of hypo-responders was found in patients with the genotype A/G for FSHR variant rs6166 (55.9%, n = 57) when compared to A/A (28.4%, n = 29), ORadj 1.87 (95% CI 1.08-3.24). No significant differences were found regarding the FORT across the genotypes for FSHR variants rs6166, rs6165, or rs1394205. Regarding the FOI, the presence of the G allele for FSHR variant rs6166 resulted in a lower FOI when compared to the A/A genotype, EMD -13.47 (95% CI -22.69 to -4.24). Regarding FSHR variant rs6165, a lower FOI was reported for genotype A/G (79.75 ± 3.35) when compared to genotype A/A (92.08 ± 6.23), EMD -13.81 (95% CI -25.41 to -2.21). LIMITATIONS, REASONS FOR CAUTION: The study was performed in relatively young women with normal ovarian reserve to eliminate biases related to age-related fertility decline; thus, caution is needed when extrapolating results to older populations. In addition, no analysis was performed for FSHB variant rs10835638 due to the very low prevalence of the genotype T/T (n = 2). WIDER IMPLICATIONS OF THE FINDINGS: Based on our results, genotyping FSHR SNPs rs6165, rs6166, rs1394205, and FSHB SNP rs10835638 prior to initiating an ovarian stimulation with rFSH in predicted normal responders should not be recommended, taking into account the minimal clinical impact of such information in this population. Future research may focus on other populations and other genes related to folliculogenesis or steroidogenesis. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by an unrestricted grant by Merck Sharp & Dohme (MSD). N.P.P. reports grants and/or personal fees from MSD, Merck Serono, Roche Diagnostics, Ferring International, Besins Healthcare, Gedeon Richter, Theramex, and Institut Biochimique SA (IBSA). N.L.V. and M.T.H. report consultancy and conference fees from Merck, Ferring, and MSD, outside the submitted work. P.D. has received honoraria for lecturing and/or research grants from MSD, Ferring International, and Merck. D.S. reports grants and/or personal fees from MSD, Ferring International, Merck Serono, Cook, and Gedeon Richter. A.R.N., B.A.M., C.S., J.M., L.H.L., P.Q.M.M., H.T., and S.G. report no conflict of interests. TRIAL REGISTRATION NUMBER: NCT03007043.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Polyzos NP, Neves AR, Drakopoulos P, et al. The effect of polymorphisms in FSHR and FSHB genes on ovarian response: a prospective multicenter multinational study in Europe and Asia. Hum Reprod. 2021. PMID: 33889959. doi:10.1093/humrep/deab068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。